Ascentage Pharma Group International EBIT

The latest EBIT for 6855.HK is $-2B as of June 2026. That compares with $-1.2B in the prior-year period — down 67.3% year over year. That is below the Healthcare sector average of $130B. Investors often review this figure alongside Ascentage Pharma Group International's historical trend and sector peers before judging valuation or financial health.

Over the past year, 6855.HK's EBIT moved from $-1.2B to $-2B — a 67.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Ascentage Pharma Group International's operating scale or balance-sheet position.

Against Healthcare companies, 6855.HK currently prints $-2B for EBIT, while the sector average sits near $130B. That is roughly 101.5% below the sector mean. Large gaps often invite a closer look at Ascentage Pharma Group International's growth, margins, and balance sheet.

A EBIT figure of $-2B for 6855.HK is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $130B. Explore the charts below for those layers of context.

After noting 6855.HK's EBIT ($-2B), review year-over-year change from $-1.2B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.